- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 491/14 - Ortho-condensed systems
Patent holdings for IPC class C07D 491/14
Total number of patents in this class: 193
10-year publication summary
27
|
19
|
12
|
9
|
13
|
3
|
19
|
13
|
13
|
6
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Merck Patent GmbH | 5829 |
13 |
Amgen Inc. | 4074 |
5 |
Dana-Farber Cancer Institute, Inc. | 2558 |
5 |
F. Hoffmann-La Roche AG | 7929 |
4 |
Genentech, Inc. | 3975 |
4 |
Gilead Sciences, Inc. | 2032 |
4 |
Jubilant Biosys Limited | 20 |
4 |
Fundacion Del Sector Publico Estatal Centro Nacional de Investigaciones Oncologicas Carlos III (f.s.p. Cnio) | 60 |
4 |
Sudo Biosciences Limited | 26 |
4 |
Novartis AG | 10867 |
3 |
LG Chem, Ltd. | 17598 |
3 |
Samsung SDI Co., Ltd. | 8174 |
3 |
Epizyme, Inc. | 370 |
3 |
Incyte Corporation | 1019 |
3 |
Rigel Pharmaceuticals, Inc. | 539 |
3 |
Rutgers, The State University of New Jersey | 1890 |
3 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2845 |
3 |
Veiled Therapeutics, LLC | 11 |
3 |
Convalife (Shanghai) Co., Ltd. | 17 |
3 |
Samsung Electronics Co., Ltd. | 145416 |
2 |
Other owners | 114 |